Figure 4.
Heat map of drug response in Pptient‐derived organoids (PDOs). (a) The sensitivity to EGFR‐TKIs was analyzed in P1, P6, and P11, which harbored EGFR mutations (
) EGFR L858R, and (
) EGFR EX20ins. (b) The chemotherapeutic sensitivity was analyzed in P1, P6, and P11 (
) EGFR L858R, and (
) EGFR EX20ins. (c) Drug sensitivity screening was performed in P9, which harbored a KRAS mutation, using EGFR‐TKIs (
) Afatinib, (
) Erlotinib, (
) Gefitinib, (
) Icotinib, (
) Neratinib, and (
) Osimertinib and chemotherapy drugs (
) Methotrexate, (
) Cytarabine, (
) Cisplatin, (
) Carboplatin, (
) Docetaxel, (
) Etoposide, (
) Gemcitabine, (
) Irinotecan, (
) Paclitaxel, (
) Pemetrexed, (
) Topotecan, (
) Vincristine, (
) Vinorelbine, and (
) Cephalomannine. EGFR‐TKI, epidermal growth factor receptor tyrosine kinase inhibitor; PDO, patient‐derived organoid.